Bicara Therapeutics Common Stock Market Value
| BCAX Stock | 20.96 0.51 2.49% |
| Symbol | Bicara |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bicara Therapeutics. If investors know Bicara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bicara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.75) |
The market value of Bicara Therapeutics is measured differently than its book value, which is the value of Bicara that is recorded on the company's balance sheet. Investors also form their own opinion of Bicara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Bicara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bicara Therapeutics' market value can be influenced by many factors that don't directly affect Bicara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bicara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bicara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bicara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Bicara Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Bicara Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Bicara Therapeutics.
| 10/29/2024 |
| 11/28/2024 |
If you would invest 0.00 in Bicara Therapeutics on October 29, 2024 and sell it all today you would earn a total of 0.00 from holding Bicara Therapeutics Common or generate 0.0% return on investment in Bicara Therapeutics over 30 days. Bicara Therapeutics is related to or competes with Stevanato Group, NetEase, Nyxoah, Allient, Franklin Wireless, and JBG SMITH. Bicara Therapeutics is entity of United States More
Bicara Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Bicara Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Bicara Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.93 | |||
| Information Ratio | 0.0526 | |||
| Maximum Drawdown | 40.03 | |||
| Value At Risk | (7.77) | |||
| Potential Upside | 8.54 |
Bicara Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bicara Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Bicara Therapeutics' standard deviation. In reality, there are many statistical measures that can use Bicara Therapeutics historical prices to predict the future Bicara Therapeutics' volatility.| Risk Adjusted Performance | 0.0652 | |||
| Jensen Alpha | 0.4237 | |||
| Total Risk Alpha | (0.46) | |||
| Sortino Ratio | 0.0631 | |||
| Treynor Ratio | 15.3 |
Bicara Therapeutics Backtested Returns
Bicara Therapeutics appears to be somewhat reliable, given 3 months investment horizon. Bicara Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0731, which signifies that the company had a 0.0731% return per unit of standard deviation over the last 3 months. We have found twenty-nine technical indicators for Bicara Therapeutics Common, which you can use to evaluate the volatility of the firm. Please makes use of Bicara Therapeutics' mean deviation of 3.63, and Risk Adjusted Performance of 0.0652 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Bicara Therapeutics holds a performance score of 5. The firm shows a Beta (market volatility) of 0.0279, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Bicara Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Bicara Therapeutics is expected to be smaller as well. Please check Bicara Therapeutics' coefficient of variation, semi variance, price action indicator, as well as the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Bicara Therapeutics' price patterns will revert.
Auto-correlation | -0.43 |
Modest reverse predictability
Bicara Therapeutics Common has modest reverse predictability. Overlapping area represents the amount of predictability between Bicara Therapeutics time series from 29th of October 2024 to 13th of November 2024 and 13th of November 2024 to 28th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Bicara Therapeutics price movement. The serial correlation of -0.43 indicates that just about 43.0% of current Bicara Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.43 | |
| Spearman Rank Test | 0.4 | |
| Residual Average | 0.0 | |
| Price Variance | 2.18 |
Bicara Therapeutics lagged returns against current returns
Autocorrelation, which is Bicara Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Bicara Therapeutics' stock expected returns. We can calculate the autocorrelation of Bicara Therapeutics returns to help us make a trade decision. For example, suppose you find that Bicara Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Bicara Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Bicara Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Bicara Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Bicara Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Bicara Therapeutics Lagged Returns
When evaluating Bicara Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Bicara Therapeutics stock have on its future price. Bicara Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Bicara Therapeutics autocorrelation shows the relationship between Bicara Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Bicara Therapeutics Common.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.